Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs

Zepbound vs Orforglipron

Editorial comparison of Zepbound (tirzepatide) and Orforglipron (orforglipron). Same drug class context, trial-anchored data, no marketing claims.

Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.

Side-by-side

DimensionZepboundOrforglipron
Generic nametirzepatideorforglipron
ManufacturerEli LillyEli Lilly
FDA approved20232026
MechanismTirzepatide is a dual incretin agonist: it hits both the GLP-1 receptor (like semaglutide) and the GIP receptor (which semaglutide doesn't).Same target as injectable GLP-1s — the GLP-1 receptor — but a non-peptide small-molecule structure.
DosingTitrated 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg, every 4 weeks. Maintenance 5-15mg weekly depending on tolerability and target weight.Once-daily oral tablet, titrated upward over several weeks to manage GI side effects. No fasting or water-timing restrictions (unlike Rybelsus).
CostList price ~$1,000-1,300/month.$149/month via LillyDirect cash-pay at launch — meaningfully below branded injectable list prices.
Pivotal trial result20.9% mean body-weight reduction at 72 weeks (15 mg dose)~14-15% mean body-weight reduction in Phase 3 (highest dose)

Full Zepbound review →

Dual GLP-1/GIP agonist for weight management. ~20% body weight loss in trials — strongest weight-loss drug currently available.

Full Orforglipron review →

First once-daily oral non-peptide GLP-1. Brand-only, launching via LillyDirect at $149/month. No injection, no compounded versions.

Frequently asked

Is Zepbound or Orforglipron more effective?+

In their pivotal trials, Zepbound reported 20.9% mean body-weight reduction at 72 weeks (15 mg dose), while Orforglipron reported ~14-15% mean body-weight reduction in Phase 3 (highest dose). Head-to-head results vary by patient profile, dose tolerated, and adherence — these trial numbers describe averages, not what every individual experiences.

How do Zepbound and Orforglipron compare on cost?+

Zepbound: List price ~$1,000-1,300/month. Lilly's patient assistance program (LillyDirect Self-Pay) offers $399-549/month for self-pay patients depending on dose. Insurance coverage similar pattern to Wegovy. Orforglipron: $149/month via LillyDirect cash-pay at launch — meaningfully below branded injectable list prices. Insurance coverage will expand through 2026-2027 as formularies add it. Real out-of-pocket depends on insurance formulary tier, manufacturer savings programs, and whether a direct-pay channel is available.

Can I switch from Zepbound to Orforglipron?+

Switching between brand-name treatments in the same drug class is common, but the conversion is not always 1:1. Discuss the switch with your prescriber — they'll usually re-titrate dosing rather than substitute equivalent strengths directly.

Are Zepbound and Orforglipron the same drug?+

No. Zepbound (tirzepatide) and Orforglipron (orforglipron) are distinct medications from Eli Lilly and Eli Lilly respectively. They may share a drug class or mechanism but differ in active ingredient, dosing, and approved use.

We may earn a commission when you click links to partners. Affiliate disclosure.